Аннотация
Background: Kazakhstan has gained experience in the treatment of Congo-Crimean hemorrhagic fever (CCHF) with ribavirin and immunized plasma. In recent years, the effectiveness of therapy in various diseases has been evaluated not only by clinical and laboratory parameters, but also by pharmacoeconomic indicators.